Genmab Announces Multiple Myeloma Antibody Program
In preclinical studies, HuMax-CD38 was effective in killing primary multiple myeloma tumor cells and a range of tumor cell lines by triggering two immune system killing mechanisms: Antibody-Dependent Cellular Cytotoxicity (ADCC) and Complement Dependent Cytotoxicity (CDC). In animal models using sensitive bioluminescence imaging, treatment with HuMax-CD38 slowed tumor growth in both preventive and therapeutic settings in SCID mice. These are mice with a deficient immune system, in which human tumor cells can grow.
Multiple myeloma is a cancer of plasma cells and accounts for approximately 1% of all cancers. The incidence of multiple myeloma is 5.2 per 100,000 people corresponding to 15,270 new cases in the US in 2004. In the US, approximately 11,000 deaths each year are related to multiple myeloma. At present, no cure is available, and the mean survival is approximately 3 years from time of diagnosis.
Topics
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous